Teladoc Health (TDOC) Financials

$7.14 +0.09 (+1.20%)

Closing price 03:59 PM Eastern

Extended Trading

$7.18 +0.04 (+0.56%)

As of 06:30 PM Eastern

Annual Income Statements for Teladoc Health

This table shows Teladoc Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-17	-58	-74	-107	-97	-99	-485	-429	-13,660	-220	-1,001
Consolidated Net Income / (Loss)	-17	-58	-74	-107	-97	-99	-485	-429	-13,660	-220	-1,001
Net Income / (Loss) Continuing Operations	-17	-58	-74	-107	-97	-99	-485	-429	-13,660	-220	-1,001
Total Pre-Tax Income	-17	-58	-74	-107	-97	-109	-576	-385	-13,663	-220	-994
Total Operating Income	-15	-56	-63	-75	-71	-80	-506	-266	-13,653	-249	-1,021
Total Gross Profit	34	56	91	172	289	369	703	1,382	1,663	1,842	1,818
Total Revenue	44	77	123	233	418	553	1,094	2,033	2,407	2,602	2,570
Operating Revenue	44	77	123	233	418	553	1,094	2,033	2,407	2,602	2,570
Total Cost of Revenue	9.93	21	32	62	129	184	391	650	744	760	751
Operating Cost of Revenue	9.93	21	32	62	129	184	391	650	744	760	751
Total Operating Expenses	49	112	154	247	360	449	1,210	1,648	15,316	2,091	2,839
Selling, General & Admin Expense	29	61	75	118	176	229	661	689	677	678	640
Marketing Expense	7.66	20	35	58	85	110	226	417	624	689	706
Research & Development Expense	7.57	14	22	34	54	65	165	312	334	349	307
Depreciation Expense	2.32	4.86	8.27	19	36	39	69	8.94	11	11	10
Amortization Expense	-	-	-	-	-	-	-	195	245	326	363
Impairment Charge	-	-	-	-	-	-	0.00	0.00	13,403	0.00	790
Restructuring Charge	0.20	0.55	6.96	13	10	6.62	88	27	23	38	22
Total Other Income / (Expense), net	-1.50	-2.20	-11	-32	-26	-29	-70	-119	-10	29	27
Interest Expense	1.50	2.20	2.59	17	26	29	69	125	22	22	24
Interest & Investment Income	-	-	-	-	-	-	-	0.78	13	47	57
Other Income / (Expense), net	-	-	-8.45	-14	-	0.34	-0.55	5.09	-0.86	4.45	-6.04
Income Tax Expense	0.39	0.04	0.51	-0.23	0.12	-11	-91	44	-3.81	0.76	7.59
Basic Earnings per Share	($10.25)	($2.91)	($1.75)	($1.93)	($1.47)	($1.38)	($5.36)	($2.73)	($84.60)	($1.34)	($5.87)
Weighted Average Basic Shares Outstanding	1.96M	19.92M	42.33M	55.43M	65.84M	71.84M	90.51M	156.94M	161.46M	164.58M	170.56M
Diluted Earnings per Share	($10.25)	($2.91)	($1.75)	($1.93)	($1.47)	($1.38)	($5.36)	($2.73)	($84.60)	($1.34)	($5.87)
Weighted Average Diluted Shares Outstanding	1.96M	19.92M	42.33M	55.43M	65.84M	71.84M	90.51M	156.94M	161.46M	164.58M	170.56M
Weighted Average Basic & Diluted Shares Outstanding	1.96M	19.92M	42.33M	55.43M	65.84M	71.84M	90.51M	160.33M	162.62M	167.04M	173.67M

This table shows Teladoc Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-73	-3,810	-69	-65	-57	-29	-82	-838	-33	-48
Consolidated Net Income / (Loss)	-73	-3,810	-69	-65	-57	-29	-82	-838	-33	-48
Net Income / (Loss) Continuing Operations	-73	-3,810	-69	-65	-57	-29	-82	-838	-33	-48
Total Pre-Tax Income	-75	-3,812	-69	-66	-60	-25	-79	-834	-32	-48
Total Operating Income	-72	-3,816	-77	-72	-65	-35	-87	-841	-44	-48
Total Gross Profit	426	449	439	462	474	467	452	454	461	452
Total Revenue	611	638	629	652	660	661	646	642	641	640
Operating Revenue	611	638	629	652	660	661	646	642	641	640
Total Cost of Revenue	186	189	190	191	186	193	195	188	180	189
Operating Cost of Revenue	186	189	190	191	186	193	195	188	180	189
Total Operating Expenses	498	4,264	516	534	539	502	539	1,296	505	500
Selling, General & Admin Expense	167	176	169	179	168	162	166	160	162	153
Marketing Expense	179	146	177	179	186	147	183	170	177	175
Research & Development Expense	85	83	87	87	84	90	81	77	72	77
Depreciation Expense	62	-169	2.92	2.95	2.47	2.79	2.83	1.70	2.67	2.98
Amortization Expense	-	-	67	73	92	95	95	95	87	87
Restructuring Charge	5.27	10	14	13	6.24	5.16	10	1.96	4.04	6.06
Total Other Income / (Expense), net	-2.92	3.64	8.56	5.52	5.17	9.71	7.92	13	12	-5.60
Interest & Investment Income	4.80	-	8.91	12	13	14	14	14	15	14
Other Income / (Expense), net	-1.57	1.75	4.91	-0.21	-1.79	1.54	-0.37	-0.56	2.24	-7.34
Income Tax Expense	-1.17	-1.84	0.68	-0.95	-2.48	3.52	2.69	3.88	0.78	0.24
Basic Earnings per Share	($0.45)	($23.35)	($0.42)	($0.40)	($0.35)	($0.17)	($0.49)	($4.92)	($0.19)	($0.27)
Weighted Average Basic Shares Outstanding	161.73M	161.46M	162.92M	164.17M	165.12M	164.58M	167.73M	170.23M	171.50M	170.56M
Diluted Earnings per Share	($0.45)	($23.35)	($0.42)	($0.40)	($0.35)	($0.17)	($0.49)	($4.92)	($0.19)	($0.27)
Weighted Average Diluted Shares Outstanding	161.73M	161.46M	162.92M	164.17M	165.12M	164.58M	167.73M	170.23M	171.50M	170.56M
Weighted Average Basic & Diluted Shares Outstanding	161.93M	162.62M	163.67M	164.95M	165.56M	167.04M	169.59M	171.22M	172.17M	173.67M

This table details how cash moves in and out of Teladoc Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	43	8.63	-5.05	-7.39	383	90	215	162	28	205	178
Net Cash From Operating Activities	-11	-47	-52	-34	-4.86	30	-54	194	189	350	294
Net Cash From Continuing Operating Activities	-11	-47	-52	-34	-4.86	30	-54	194	189	350	294
Net Income / (Loss) Continuing Operations	-17	-58	-74	-107	-97	-99	-485	-429	-13,660	-220	-1,001
Consolidated Net Income / (Loss)	-17	-58	-74	-107	-97	-99	-485	-429	-13,660	-220	-1,001
Depreciation Expense	2.32	4.86	8.27	19	36	39	71	12	11	11	10
Amortization Expense	-	-	7.72	14	0.00	6.00	6.90	207	256	338	373
Non-Cash Adjustments To Reconcile Net Income	1.95	6.37	10	39	60	96	534	405	13,637	212	950
Changes in Operating Assets and Liabilities, net	1.41	-0.39	-4.04	0.41	-3.38	-12	-181	-2.19	-56	9.74	-37
Net Cash From Investing Activities	-16	-108	26	-448	-257	25	-591	-73	-168	-156	-124
Net Cash From Continuing Investing Activities	-16	-108	26	-448	-257	25	-591	-73	-168	-156	-124
Purchase of Property, Plant & Equipment	-1.07	-6.28	-2.11	-2.63	-4.01	-3.51	-26	-64	-173	-156	-124
Sale and/or Maturity of Investments	-	20	111	86	84	47	2.50	61	2.51	0.00	0.00
Other Investing Activities, net	-	-	-	-	-	0.00	0.00	8.72	2.51	0.00	0.00
Net Cash From Financing Activities	70	164	21	475	646	35	859	41	6.50	11	8.31
Net Cash From Continuing Financing Activities	70	164	21	475	646	35	859	41	6.50	11	8.31
Repayment of Debt	-	-6.33	-17	-226	0.00	0.00	-34	-5.07	-5.89	-0.28	-0.00
Issuance of Common Equity	-	163	0.25	261	333	3.38	4.72	17	6.50	9.65	4.75
Other Financing Activities, net	0.75	0.43	2.60	177	33	32	117	29	5.88	1.48	3.57
Cash Interest Paid	1.19	2.00	2.39	9.45	10	12	15	19	17	17	17
Cash Income Taxes Paid	-	-	-	0.14	0.44	1.31	1.32	3.97	2.51	7.24	8.95

This table details how cash moves in and out of Teladoc Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	22	16	-29	69	73	92	-25	65	80	58
Net Cash From Operating Activities	63	66	13	101	106	130	8.92	89	110	86
Net Cash From Continuing Operating Activities	63	66	13	101	106	130	8.92	89	110	86
Net Income / (Loss) Continuing Operations	-73	-3,810	-69	-65	-57	-29	-82	-838	-33	-48
Consolidated Net Income / (Loss)	-73	-3,810	-69	-65	-57	-29	-82	-838	-33	-48
Depreciation Expense	63	-171	2.92	2.95	2.47	2.79	2.83	1.70	2.67	2.98
Amortization Expense	2.73	247	70	75	94	98	98	97	89	89
Non-Cash Adjustments To Reconcile Net Income	63	3,825	53	59	57	43	44	834	38	34
Changes in Operating Assets and Liabilities, net	7.88	-26	-44	29	8.80	16	-54	-6.62	14	8.99
Net Cash From Investing Activities	-41	-54	-46	-37	-38	-37	-36	-28	-31	-30
Net Cash From Continuing Investing Activities	-41	-54	-46	-37	-38	-37	-36	-28	-31	-30
Purchase of Property, Plant & Equipment	-43	-54	-46	-37	-38	-37	-36	-28	-31	-30
Net Cash From Financing Activities	0.63	4.38	3.35	4.21	5.07	-1.78	1.75	3.81	0.70	2.06
Net Cash From Continuing Financing Activities	0.63	4.38	3.35	4.21	5.07	-1.78	1.75	3.81	0.70	2.06
Issuance of Common Equity	1.41	3.12	2.73	2.70	3.16	1.05	1.52	1.28	0.92	1.03
Other Financing Activities, net	1.21	-0.36	0.79	1.34	1.91	-2.55	0.24	2.52	-0.23	1.03
Cash Interest Paid	0.02	8.67	0.19	8.48	0.01	8.74	0.00	8.66	-	8.66
Cash Income Taxes Paid	0.34	1.61	0.35	0.44	5.53	0.92	-0.25	4.86	2.62	1.71

This table presents Teladoc Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	92	230	304	824	1,529	1,603	17,755	17,735	4,345	4,392	3,517
Total Current Assets	54	152	83	156	533	588	1,060	1,225	1,315	1,489	1,664
Cash & Equivalents	46	55	50	43	424	514	733	893	918	1,124	1,298
Accounts Receivable	6.84	12	14	27	44	57	169	169	211	217	214
Inventories, net	-	-	-	-	-	0.00	56	73	56	30	38
Prepaid Expenses	0.97	2.10	3.10	6.84	11	14	47	87	130	118	113
Plant, Property, & Equipment, net	1.07	6.26	7.48	8.96	10	10	29	27	30	32	29
Total Noncurrent Assets	36	72	213	659	986	1,005	16,667	16,482	3,000	2,871	1,823
Goodwill	28	56	188	499	737	746	14,581	14,504	1,073	1,073	283
Intangible Assets	7.53	15	25	160	247	225	2,021	1,910	1,837	1,678	1,431
Other Noncurrent Operating Assets	0.30	0.29	0.42	0.86	1.40	33	65	67	90	120	109
Total Liabilities & Shareholders' Equity	92	230	304	824	1,529	1,603	17,755	17,735	4,345	4,392	3,517
Total Liabilities	39	51	73	265	516	589	1,871	1,680	2,038	2,066	2,025
Total Current Liabilities	10	18	21	40	62	90	333	331	400	421	942
Short-Term Debt	0.83	1.25	2.00	-	-	0.00	43	-	-	0.00	551
Accounts Payable	2.21	2.21	2.24	3.88	7.77	9.08	46	47	48	44	33
Accrued Expenses	3.92	8.20	7.98	19	27	34	84	103	169	179	202
Current Deferred Revenue	-	-	-	-	-	12	52	76	102	96	79
Current Employee Benefit Liabilities	3.36	6.33	8.86	17	28	34	95	92	82	103	76
Total Noncurrent Liabilities	28	33	52	225	453	499	1,539	1,349	1,638	1,646	1,084
Long-Term Debt	25	25	42	207	415	440	1,380	1,226	1,535	1,539	991
Capital Lease Obligations	-	-	-	-	-	25	43	-	38	43	32
Noncurrent Deferred Revenue	-	-	-	-	-	2.30	12	3.83	12	14	9.79
Noncurrent Deferred & Payable Income Tax Liabilities	0.48	1.19	1.69	13	32	22	102	76	51	49	50
Other Noncurrent Operating Liabilities	2.77	6.78	7.61	4.88	6.19	9.24	1.62	53	1.62	1.08	0.72
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-68	179	231	559	1,013	1,014	15,884	16,046	2,308	2,326	1,491
Total Preferred & Common Equity	-68	179	231	559	1,013	1,014	15,884	16,046	2,308	2,326	1,491
Total Common Equity	-68	179	231	559	1,013	1,014	15,884	16,046	2,308	2,326	1,491
Common Stock	4.96	309	436	866	1,435	1,539	16,858	17,473	17,359	17,592	17,759
Retained Earnings	-72	-131	-205	-312	-409	-508	-993	-1,421	-15,008	-15,229	-16,230
Accumulated Other Comprehensive Income / (Loss)	-	-0.04	-0.00	4.09	-13	-17	19	-6.29	-43	-37	-38

This table presents Teladoc Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	8,104	4,309	4,316	4,328	4,321	3,524	3,529
Total Current Assets	1,288	1,287	1,321	1,387	1,486	1,547	1,609
Cash & Equivalents	900	889	959	1,031	1,098	1,162	1,244
Accounts Receivable	202	216	215	206	214	218	212
Inventories, net	59	46	34	36	32	35	37
Prepaid Expenses	127	136	113	115	142	131	116
Plant, Property, & Equipment, net	27	30	30	33	30	29	28
Total Noncurrent Assets	6,789	2,993	2,965	2,908	2,805	1,948	1,892
Goodwill	4,846	1,073	1,073	1,073	1,073	283	283
Intangible Assets	1,854	1,816	1,784	1,728	1,614	1,547	1,497
Other Noncurrent Operating Assets	89	104	108	107	118	117	112
Total Liabilities & Shareholders' Equity	8,104	4,309	4,316	4,328	4,321	3,524	3,529
Total Liabilities	2,051	2,010	2,021	2,034	2,032	2,022	2,021
Total Current Liabilities	411	381	383	403	389	931	931
Short-Term Debt	-	-	-	-	-	551	551
Accounts Payable	71	39	16	26	38	56	38
Accrued Expenses	177	185	193	193	199	174	188
Current Deferred Revenue	90	96	107	99	101	95	88
Current Employee Benefit Liabilities	63	51	67	85	51	55	66
Total Noncurrent Liabilities	1,640	1,629	1,638	1,631	1,643	1,091	1,089
Long-Term Debt	1,534	1,536	1,537	1,538	1,540	990	991
Capital Lease Obligations	41	-	37	34	40	38	37
Noncurrent Deferred Revenue	11	4.12	14	13	15	12	10
Noncurrent Deferred & Payable Income Tax Liabilities	52	51	48	44	47	51	51
Other Noncurrent Operating Liabilities	1.63	46	1.74	1.69	1.02	1.01	0.74
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	6,053	2,291	2,295	2,294	2,289	1,502	1,508
Total Preferred & Common Equity	6,053	2,291	2,295	2,294	2,289	1,502	1,508
Total Common Equity	6,053	2,291	2,295	2,294	2,289	1,502	1,508
Common Stock	17,300	17,410	17,477	17,535	17,638	17,689	17,726
Retained Earnings	-11,198	-15,078	-15,143	-15,200	-15,311	-16,148	-16,181
Accumulated Other Comprehensive Income / (Loss)	-49	-41	-39	-42	-39	-39	-37

This table displays calculated financial ratios and metrics derived from Teladoc Health's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	118.67%	77.78%	59.15%	89.42%	79.14%	32.40%	97.71%	85.81%	18.41%	8.13%	-1.26%
EBITDA Growth	-150.83%	-296.90%	-8.27%	-2.12%	37.38%	0.30%	-1,120.21%	90.46%	-32,611.72%	100.78%	-715.68%
EBIT Growth	-158.14%	-268.22%	-27.49%	-25.87%	20.85%	-13.05%	-532.92%	48.61%	-5,140.62%	98.21%	-320.68%
NOPAT Growth	-158.14%	-268.22%	-12.33%	-20.31%	6.02%	-13.53%	-529.55%	47.55%	-5,039.92%	98.18%	-310.73%
Net Income Growth	-183.05%	-240.55%	-27.91%	-43.88%	9.08%	-1.83%	-390.71%	11.61%	-3,085.58%	98.39%	-354.35%
EPS Growth	-27.33%	71.61%	39.86%	-10.29%	23.83%	6.12%	-288.41%	49.07%	-2,998.90%	98.42%	-338.06%
Operating Cash Flow Growth	-87.66%	-315.36%	-9.95%	33.61%	85.89%	714.59%	-279.15%	462.52%	-2.42%	84.91%	-16.10%
Free Cash Flow Firm Growth	0.00%	-71.18%	-150.64%	-162.45%	27.16%	80.44%	-22,887.30%	100.01%	327,645.32%	-99.87%	5,966.24%
Invested Capital Growth	0.00%	107.22%	209.46%	207.40%	47.41%	1.38%	1,621.02%	-1.13%	-81.91%	-6.04%	-36.53%
Revenue Q/Q Growth	0.00%	0.00%	13.62%	20.53%	12.25%	6.50%	26.16%	9.18%	3.59%	0.88%	-0.77%
EBITDA Q/Q Growth	0.00%	0.00%	2.53%	-16.52%	20.12%	10.51%	-2,004.20%	91.64%	-38.96%	102.83%	-5.54%
EBIT Q/Q Growth	0.00%	0.00%	-11.51%	-39.73%	8.67%	3.13%	-698.33%	61.51%	-38.17%	93.93%	-2.19%
NOPAT Q/Q Growth	0.00%	0.00%	1.75%	-17.68%	8.67%	2.72%	-697.48%	61.09%	-38.20%	93.83%	-1.30%
Net Income Q/Q Growth	0.00%	0.00%	1.00%	-39.29%	16.73%	5.57%	-340.18%	47.18%	-38.53%	94.49%	-1.99%
EPS Q/Q Growth	0.00%	0.00%	-119.23%	-33.10%	23.83%	5.48%	-274.83%	60.38%	-38.05%	94.54%	-1.73%
Operating Cash Flow Q/Q Growth	0.00%	-22.04%	9.22%	0.75%	66.74%	110.00%	-167.27%	4,769.96%	-8.53%	22.60%	-13.08%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-1.88%	4.84%	-126.74%	-1,347.82%	100.01%	39.11%	-99.54%	4.86%
Invested Capital Q/Q Growth	0.00%	0.00%	-1.10%	-0.20%	-1.52%	2.75%	730.56%	-0.24%	-55.97%	-1.83%	-4.07%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	77.19%	72.81%	74.04%	73.58%	69.20%	66.66%	64.27%	68.01%	69.09%	70.80%	70.76%
EBITDA Margin	-29.48%	-65.80%	-44.76%	-24.13%	-8.44%	-6.35%	-39.20%	-2.01%	-556.18%	4.02%	-25.07%
Operating Margin	-34.81%	-72.09%	-50.88%	-32.32%	-16.95%	-14.54%	-46.29%	-13.07%	-567.27%	-9.55%	-39.73%
EBIT Margin	-34.81%	-72.09%	-57.75%	-38.37%	-16.95%	-14.48%	-46.34%	-12.82%	-567.30%	-9.38%	-39.96%
Profit (Net Income) Margin	-39.14%	-74.98%	-60.26%	-45.77%	-23.23%	-17.87%	-44.35%	-21.09%	-567.53%	-8.47%	-38.97%
Tax Burden Percent	102.33%	100.06%	100.69%	99.79%	100.12%	90.32%	84.23%	111.47%	99.97%	100.35%	100.76%
Interest Burden Percent	109.89%	103.94%	103.64%	119.54%	136.85%	136.65%	113.62%	147.64%	100.07%	89.96%	96.76%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-64.93%	-77.82%	-31.65%	-12.37%	-6.23%	-5.89%	-4.05%	-1.13%	-98.84%	-6.06%	-31.41%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.37%	-48.95%	14.25%	-181.99%	-453.93%	67.79%	-45.71%	-49.30%	-931.96%	-14.39%	-109.53%
Return on Net Nonoperating Assets (RNNOA)	0.91%	27.76%	-4.60%	-14.67%	-6.13%	-3.86%	-1.70%	-1.56%	-50.01%	-3.46%	-21.06%
Return on Equity (ROE)	-64.01%	-50.06%	-36.25%	-27.04%	-12.35%	-9.75%	-5.74%	-2.69%	-148.85%	-9.51%	-52.46%
Cash Return on Invested Capital (CROIC)	-264.93%	-147.62%	-133.96%	-114.18%	-44.55%	-7.26%	-182.08%	0.01%	39.87%	0.17%	13.28%
Operating Return on Assets (OROA)	-16.50%	-34.69%	-26.67%	-15.87%	-6.02%	-5.12%	-5.24%	-1.47%	-123.68%	-5.59%	-25.97%
Return on Assets (ROA)	-18.55%	-36.08%	-27.83%	-18.93%	-8.25%	-6.31%	-5.01%	-2.42%	-123.73%	-5.04%	-25.32%
Return on Common Equity (ROCE)	81.21%	-23.98%	-36.25%	-27.04%	-12.35%	-9.75%	-5.74%	-2.69%	-148.85%	-9.51%	-52.46%
Return on Equity Simple (ROE_SIMPLE)	25.23%	-32.49%	-32.15%	-19.11%	-9.58%	-9.75%	-3.05%	-2.67%	-591.90%	-9.47%	-67.15%
Net Operating Profit after Tax (NOPAT)	-11	-39	-44	-53	-50	-56	-354	-186	-9,557	-174	-715
NOPAT Margin	-24.36%	-50.46%	-35.62%	-22.62%	-11.87%	-10.18%	-32.40%	-9.15%	-397.09%	-6.69%	-27.81%
Net Nonoperating Expense Percent (NNEP)	-62.56%	-28.87%	-45.90%	169.62%	447.71%	-73.68%	41.67%	48.17%	833.12%	8.33%	78.12%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-246.25%	-4.45%	-23.31%
Cost of Revenue to Revenue	22.81%	27.19%	25.96%	26.42%	30.80%	33.34%	35.73%	31.99%	30.91%	29.20%	29.24%
SG&A Expenses to Revenue	67.22%	78.77%	60.74%	50.48%	42.13%	41.45%	60.40%	33.88%	28.13%	26.07%	24.93%
R&D to Revenue	17.40%	18.36%	17.71%	14.77%	13.01%	11.68%	15.08%	15.34%	13.86%	13.39%	11.96%
Operating Expenses to Revenue	111.99%	144.90%	124.92%	105.90%	86.15%	81.20%	110.57%	81.08%	636.36%	80.35%	110.49%
Earnings before Interest and Taxes (EBIT)	-15	-56	-71	-90	-71	-80	-507	-261	-13,654	-244	-1,027
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-51	-55	-56	-35	-35	-429	-41	-13,386	105	-644
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	3.87	3.29	3.55	3.43	5.98	1.82	0.92	1.66	1.53	1.05
Price to Tangible Book Value (P/TBV)	0.00	6.46	42.64	0.00	121.82	142.61	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	8.92	6.17	8.51	8.32	10.95	26.50	7.23	1.59	1.37	0.61
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	8.56	3.52	3.21	3.59	6.24	1.79	0.92	1.51	1.45	1.04
Enterprise Value to Revenue (EV/Rev)	0.00	7.49	5.99	8.87	8.16	10.86	27.12	7.39	1.86	1.55	0.72
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	38.48	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	201.15	0.00	77.47	23.69	11.50	6.27
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	12,776.34	1.16	807.89	6.09
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.49	0.15	0.19	0.37	0.41	0.46	0.09	0.08	0.68	0.68	1.06
Long-Term Debt to Equity	0.47	0.14	0.18	0.37	0.41	0.46	0.09	0.08	0.68	0.68	0.69
Financial Leverage	-0.39	-0.57	-0.32	0.08	0.01	-0.06	0.04	0.03	0.05	0.24	0.19
Leverage Ratio	1.73	1.39	1.30	1.43	1.50	1.54	1.15	1.11	1.20	1.89	2.07
Compound Leverage Factor	1.90	1.44	1.35	1.71	2.05	2.11	1.30	1.64	1.20	1.70	2.00
Debt to Total Capital	32.71%	12.91%	16.14%	27.06%	29.04%	31.46%	8.45%	7.10%	40.54%	40.47%	51.36%
Short-Term Debt to Total Capital	1.05%	0.61%	0.73%	0.00%	0.00%	0.00%	0.25%	0.00%	0.00%	0.00%	17.97%
Long-Term Debt to Total Capital	31.65%	12.30%	15.41%	27.06%	29.04%	31.46%	8.20%	7.10%	40.54%	40.47%	33.39%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	152.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-85.37%	87.09%	83.86%	72.94%	70.96%	68.54%	91.55%	92.90%	59.46%	59.53%	48.64%
Debt to EBITDA	-2.02	-0.52	-0.81	-3.68	-11.76	-13.24	-3.42	-29.95	-0.12	15.12	-2.44
Net Debt to EBITDA	1.60	2.18	0.39	-1.51	1.81	1.47	-1.58	-8.06	-0.05	4.38	-0.43
Long-Term Debt to EBITDA	-1.95	-0.50	-0.77	-3.68	-11.76	-13.24	-3.32	-29.95	-0.12	15.12	-1.59
Debt to NOPAT	-2.44	-0.68	-1.01	-3.93	-8.36	-8.27	-4.13	-6.59	-0.16	-9.09	-2.20
Net Debt to NOPAT	1.94	2.84	0.49	-1.61	1.29	0.92	-1.91	-1.77	-0.07	-2.63	-0.39
Long-Term Debt to NOPAT	-2.36	-0.65	-0.97	-3.93	-8.36	-8.27	-4.01	-6.59	-0.16	-9.09	-1.43
Altman Z-Score	0.00	7.54	5.19	4.05	4.16	6.28	9.23	5.27	-13.27	-3.12	-5.98
Noncontrolling Interest Sharing Ratio	226.87%	52.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.28	8.43	3.93	3.87	8.53	6.52	3.19	3.70	3.29	3.54	1.77
Quick Ratio	5.16	8.31	3.78	3.70	8.36	6.37	2.87	3.22	2.82	3.19	1.61
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-43	-74	-186	-487	-355	-69	-15,955	1.18	3,855	4.98	302
Operating Cash Flow to CapEx	-1,062.58%	-751.89%	-2,460.86%	-1,308.05%	0.00%	850.97%	-205.48%	303.42%	109.57%	223.87%	236.74%
Free Cash Flow to Firm to Interest Expense	-28.87	-33.69	-71.74	-27.86	-13.59	-2.36	-231.14	0.01	175.69	0.22	12.70
Operating Cash Flow to Interest Expense	-7.58	-21.46	-20.04	-1.97	-0.19	1.02	-0.78	1.55	8.63	15.71	12.34
Operating Cash Flow Less CapEx to Interest Expense	-8.29	-24.31	-20.86	-2.12	-0.13	0.90	-1.15	1.04	0.75	8.69	7.13
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.48	0.46	0.41	0.36	0.35	0.11	0.11	0.22	0.60	0.65
Accounts Receivable Turnover	6.36	8.16	9.50	11.41	11.83	11.01	9.67	12.02	12.68	12.16	11.91
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.04	11.50	17.71	22.21
Fixed Asset Turnover	40.87	21.13	17.93	28.38	43.73	54.13	56.32	72.88	84.64	84.39	83.54
Accounts Payable Turnover	4.49	9.51	14.37	20.14	22.09	21.90	14.18	13.94	15.67	16.64	19.57
Days Sales Outstanding (DSO)	57.35	44.75	38.44	32.00	30.86	33.15	37.74	30.37	28.78	30.01	30.65
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	36.37	31.75	20.62	16.43
Days Payable Outstanding (DPO)	81.24	38.36	25.40	18.12	16.52	16.66	25.73	26.18	23.29	21.93	18.65
Cash Conversion Cycle (CCC)	-23.89	6.38	13.04	13.87	14.34	16.49	12.01	40.55	37.23	28.70	28.44
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	33	68	209	644	949	962	16,563	16,375	2,963	2,784	1,767
Invested Capital Turnover	2.66	1.54	0.89	0.55	0.52	0.58	0.12	0.12	0.25	0.91	1.13
Increase / (Decrease) in Invested Capital	33	35	142	434	305	13	15,600	-187	-13,413	-179	-1,017
Enterprise Value (EV)	0.00	580	738	2,070	3,411	6,008	29,665	15,029	4,485	4,026	1,841
Market Capitalization	0.00	691	760	1,985	3,475	6,060	28,986	14,699	3,830	3,568	1,565
Book Value per Share	($34.41)	$4.64	$5.02	$9.81	$14.45	$14.01	$109.57	$100.23	$14.25	$14.05	$8.66
Tangible Book Value per Share	($52.74)	$2.78	$0.39	($1.75)	$0.41	$0.59	($4.96)	($2.30)	($3.72)	($2.57)	($1.30)
Total Capital	79	205	275	766	1,428	1,479	17,349	17,271	3,881	3,908	3,065
Total Debt	26	26	44	207	415	465	1,465	1,226	1,573	1,582	1,574
Total Long-Term Debt	25	25	42	207	415	465	1,423	1,226	1,573	1,582	1,024
Net Debt	-21	-111	-21	85	-64	-52	679	330	655	458	276
Capital Expenditures (CapEx)	1.07	6.28	2.11	2.63	-1.52	3.51	26	64	173	156	124
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.43	-2.51	-2.16	-6.40	-8.24	-19	-17	-1.59	-2.56	-55	-25
Debt-free Net Working Capital (DFNWC)	45	135	64	116	470	498	770	894	916	1,068	1,273
Net Working Capital (NWC)	44	134	62	116	470	498	727	894	916	1,068	722
Net Nonoperating Expense (NNE)	6.43	19	30	54	47	43	131	243	4,102	46	287
Net Nonoperating Obligations (NNO)	-21	-111	-21	85	-64	-52	679	330	655	458	276
Total Depreciation and Amortization (D&A)	2.32	4.86	16	33	36	45	78	220	268	349	383
Debt-free, Cash-free Net Working Capital to Revenue	-3.28%	-3.24%	-1.76%	-2.74%	-1.97%	-3.48%	-1.56%	-0.08%	-0.11%	-2.12%	-0.98%
Debt-free Net Working Capital to Revenue	103.40%	174.25%	51.68%	49.69%	112.54%	89.97%	70.34%	44.00%	38.04%	41.06%	49.55%
Net Working Capital to Revenue	101.49%	172.64%	50.05%	49.69%	112.54%	89.97%	66.45%	44.00%	38.04%	41.06%	28.11%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($10.25)	($2.91)	($1.75)	($1.93)	($1.47)	($1.38)	($5.36)	($2.73)	($84.60)	($1.34)	($5.87)
Adjusted Weighted Average Basic Shares Outstanding	1.96M	38.56M	54.24M	61.73M	70.77M	73.01M	152.70M	156.94M	161.46M	164.58M	170.56M
Adjusted Diluted Earnings per Share	($10.25)	($2.91)	($1.75)	($1.93)	($1.47)	($1.38)	($5.36)	($2.73)	($84.60)	($1.34)	($5.87)
Adjusted Weighted Average Diluted Shares Outstanding	1.96M	38.56M	54.24M	61.73M	70.77M	73.01M	152.70M	156.94M	161.46M	164.58M	170.56M
Adjusted Basic & Diluted Earnings per Share	($10.25)	($2.91)	($1.75)	($1.93)	($1.47)	($1.38)	($5.36)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.96M	19.92M	42.33M	55.43M	65.84M	71.84M	90.51M	160.33M	162.62M	167.04M	173.67M
Normalized Net Operating Profit after Tax (NOPAT)	-9.55	-32	-36	-44	-46	-52	-293	-167	-159	-147	-146
Normalized NOPAT Margin	-21.94%	-41.93%	-29.32%	-18.66%	-11.05%	-9.34%	-26.76%	-8.23%	-6.61%	-5.66%	-5.69%
Pre Tax Income Margin	-38.25%	-74.93%	-59.85%	-45.87%	-23.20%	-19.78%	-52.65%	-18.92%	-567.69%	-8.44%	-38.67%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-10.11	-25.37	-27.48	-5.12	-2.71	-2.73	-7.34	-2.09	-622.22	-10.96	-43.14
NOPAT to Interest Expense	-7.07	-17.76	-16.95	-3.02	-1.90	-1.92	-5.14	-1.49	-435.53	-7.81	-30.02
EBIT Less CapEx to Interest Expense	-10.82	-28.22	-28.29	-5.27	-2.66	-2.85	-7.72	-2.60	-630.10	-17.97	-48.35
NOPAT Less CapEx to Interest Expense	-7.79	-20.61	-17.76	-3.17	-1.84	-2.04	-5.51	-2.00	-443.40	-14.83	-35.23
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-2.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Teladoc Health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	17.20%	15.06%	11.30%	10.13%	7.99%	3.58%	2.68%	-1.53%	-2.99%	-3.03%
EBITDA Growth	-33.79%	-24,698.78%	100.01%	100.21%	485.51%	101.80%	1,920.65%	-11,826.25%	63.70%	-46.34%
EBIT Growth	-20.26%	-9,016.52%	98.92%	97.68%	9.26%	99.12%	-21.19%	-1,071.45%	36.61%	-65.62%
NOPAT Growth	-18.41%	-9,109.86%	98.84%	97.69%	9.77%	99.08%	-13.00%	-1,074.05%	31.40%	-37.44%
Net Income Growth	12.88%	-34,584.31%	98.96%	97.90%	22.32%	99.24%	-18.29%	-1,185.22%	41.70%	-67.56%
EPS Growth	15.09%	-77,733.33%	98.99%	97.92%	22.22%	99.27%	-16.67%	-1,130.00%	45.71%	-58.82%
Operating Cash Flow Growth	-17.72%	-21.22%	141.44%	9.42%	67.56%	98.45%	-32.20%	-12.35%	4.33%	-33.96%
Free Cash Flow Firm Growth	166.63%	6,693.44%	259.52%	-49.13%	-60.07%	-98.56%	-98.44%	-89.43%	-74.98%	536.70%
Invested Capital Growth	-59.01%	-81.91%	-70.24%	-57.07%	-57.86%	-6.04%	-5.73%	-34.10%	-35.04%	-36.53%
Revenue Q/Q Growth	3.21%	4.30%	-1.33%	3.68%	1.20%	0.04%	-2.18%	-0.57%	-0.30%	0.00%
EBITDA Q/Q Growth	99.74%	-47,406.15%	100.02%	883.70%	378.80%	121.88%	-80.85%	-5,808.58%	106.68%	-27.26%
EBIT Q/Q Growth	97.63%	-5,102.94%	98.11%	0.48%	7.43%	49.57%	-160.83%	-862.04%	94.99%	-31.77%
NOPAT Q/Q Growth	97.68%	-5,219.33%	97.98%	7.08%	9.66%	45.80%	-148.35%	-865.48%	94.72%	-8.59%
Net Income Q/Q Growth	97.63%	-5,085.46%	98.18%	5.85%	12.43%	49.38%	-183.45%	-922.93%	96.03%	-45.48%
EPS Q/Q Growth	97.66%	-5,088.89%	98.20%	4.76%	12.50%	51.43%	-188.24%	-904.08%	96.14%	-42.11%
Operating Cash Flow Q/Q Growth	-31.85%	4.01%	-79.93%	669.09%	4.37%	23.18%	-93.14%	894.20%	24.23%	-22.03%
Free Cash Flow Firm Q/Q Growth	28.39%	11.47%	-35.91%	-44.53%	0.76%	-95.99%	-30.50%	276.09%	138.50%	2.13%
Invested Capital Q/Q Growth	-0.74%	-55.97%	-0.81%	-0.97%	-2.56%	-1.83%	-0.48%	-30.78%	-3.95%	-4.07%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.64%	70.38%	69.79%	70.79%	71.83%	70.72%	69.89%	70.73%	71.94%	70.50%
EBITDA Margin	-1.29%	-586.13%	0.10%	0.97%	4.59%	10.19%	2.01%	-115.63%	7.75%	5.64%
Operating Margin	-11.73%	-598.32%	-12.25%	-10.98%	-9.80%	-5.31%	-13.48%	-130.93%	-6.93%	-7.53%
EBIT Margin	-11.99%	-598.05%	-11.47%	-11.01%	-10.07%	-5.08%	-13.54%	-131.02%	-6.58%	-8.67%
Profit (Net Income) Margin	-12.02%	-597.46%	-11.00%	-9.99%	-8.64%	-4.37%	-12.67%	-130.39%	-5.20%	-7.56%
Tax Burden Percent	98.43%	99.95%	100.99%	98.56%	95.83%	113.85%	103.40%	100.47%	102.40%	100.49%
Interest Burden Percent	101.84%	99.95%	94.95%	92.04%	89.54%	75.65%	90.52%	99.06%	77.07%	86.71%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-1.65%	-104.25%	-3.31%	-4.02%	-3.70%	-3.37%	-8.66%	-99.07%	-5.37%	-5.95%
ROIC Less NNEP Spread (ROIC-NNEP)	-5.86%	-335.61%	-5.52%	-6.31%	-5.63%	-4.15%	-12.36%	-147.35%	-5.87%	-9.95%
Return on Net Nonoperating Assets (RNNOA)	-0.29%	-18.01%	-0.67%	-0.99%	-0.82%	-1.00%	-3.05%	-40.00%	-1.35%	-1.91%
Return on Equity (ROE)	-1.94%	-122.26%	-3.97%	-5.00%	-4.52%	-4.36%	-11.71%	-139.07%	-6.73%	-7.86%
Cash Return on Invested Capital (CROIC)	23.95%	39.87%	31.14%	21.54%	22.43%	0.17%	-0.44%	11.30%	12.33%	13.28%
Operating Return on Assets (OROA)	-2.16%	-130.38%	-3.68%	-4.49%	-4.18%	-3.03%	-8.22%	-87.21%	-4.34%	-5.64%
Return on Assets (ROA)	-2.17%	-130.25%	-3.53%	-4.07%	-3.59%	-2.61%	-7.69%	-86.79%	-3.42%	-4.91%
Return on Common Equity (ROCE)	-1.94%	-122.26%	-3.97%	-5.00%	-4.52%	-4.36%	-11.71%	-139.07%	-6.73%	-7.86%
Return on Equity Simple (ROE_SIMPLE)	-162.91%	0.00%	-307.88%	-175.06%	-174.43%	0.00%	-10.18%	-66.94%	-65.11%	0.00%
Net Operating Profit after Tax (NOPAT)	-50	-2,671	-54	-50	-45	-25	-61	-589	-31	-34
NOPAT Margin	-8.21%	-418.83%	-8.58%	-7.69%	-6.86%	-3.72%	-9.44%	-91.65%	-4.85%	-5.27%
Net Nonoperating Expense Percent (NNEP)	4.22%	231.35%	2.21%	2.30%	1.93%	0.78%	3.70%	48.28%	0.50%	4.00%
Return On Investment Capital (ROIC_SIMPLE)	-	-68.82%	-	-	-	-0.63%	-	-	-	-1.10%
Cost of Revenue to Revenue	30.36%	29.62%	30.21%	29.21%	28.17%	29.28%	30.11%	29.27%	28.06%	29.50%
SG&A Expenses to Revenue	27.27%	27.62%	26.80%	27.49%	25.45%	24.59%	25.70%	24.90%	25.25%	23.84%
R&D to Revenue	13.84%	13.00%	13.82%	13.38%	12.77%	13.62%	12.60%	11.95%	11.30%	11.98%
Operating Expenses to Revenue	81.37%	668.70%	82.04%	81.78%	81.64%	76.03%	83.38%	201.66%	78.87%	78.03%
Earnings before Interest and Taxes (EBIT)	-73	-3,814	-72	-72	-67	-34	-87	-842	-42	-56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-7.87	-3,738	0.64	6.34	30	67	13	-743	50	36
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.68	1.66	1.84	1.81	1.34	1.53	1.09	1.10	1.04	1.05
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.76	1.59	1.70	1.64	1.19	1.37	0.95	0.64	0.61	0.61
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.71	1.51	1.65	1.64	1.27	1.45	1.08	1.08	1.03	1.04
Enterprise Value to Revenue (EV/Rev)	2.05	1.86	1.97	1.88	1.40	1.55	1.14	0.80	0.74	0.72
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	38.48	24.93	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	23.07	23.69	20.75	19.59	12.64	11.50	8.62	6.22	5.64	6.27
Enterprise Value to Free Cash Flow (EV/FCFF)	1.72	1.16	2.44	4.56	3.36	807.89	0.00	7.60	6.61	6.09
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.26	0.68	0.67	0.69	0.69	0.68	0.69	1.05	1.05	1.06
Long-Term Debt to Equity	0.26	0.68	0.67	0.69	0.69	0.68	0.69	0.68	0.68	0.69
Financial Leverage	0.05	0.05	0.12	0.16	0.15	0.24	0.25	0.27	0.23	0.19
Leverage Ratio	1.17	1.20	1.35	1.48	1.49	1.89	1.88	2.06	2.07	2.07
Compound Leverage Factor	1.19	1.20	1.28	1.36	1.33	1.43	1.71	2.05	1.59	1.80
Debt to Total Capital	20.65%	40.54%	40.14%	40.68%	40.66%	40.47%	40.83%	51.23%	51.14%	51.36%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	17.88%	17.85%	17.97%
Long-Term Debt to Total Capital	20.65%	40.54%	40.14%	40.68%	40.66%	40.47%	40.83%	33.35%	33.30%	33.39%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	79.35%	59.46%	59.86%	59.32%	59.34%	59.53%	59.17%	48.77%	48.86%	48.64%
Debt to EBITDA	-0.16	-0.12	-0.23	-0.42	-0.43	15.12	13.21	-2.51	-2.59	-2.44
Net Debt to EBITDA	-0.07	-0.05	-0.10	-0.16	-0.15	4.38	4.03	-0.66	-0.55	-0.43
Long-Term Debt to EBITDA	-0.16	-0.12	-0.23	-0.42	-0.43	15.12	13.21	-1.63	-1.68	-1.59
Debt to NOPAT	-0.23	-0.16	-0.31	-0.56	-0.56	-9.09	-8.73	-2.19	-2.24	-2.20
Net Debt to NOPAT	-0.10	-0.07	-0.13	-0.22	-0.19	-2.63	-2.66	-0.58	-0.47	-0.39
Long-Term Debt to NOPAT	-0.23	-0.16	-0.31	-0.56	-0.56	-9.09	-8.73	-1.43	-1.46	-1.43
Altman Z-Score	-0.35	-5.80	-2.87	-2.89	-3.19	-2.96	-3.38	-5.76	-5.03	-5.07
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.13	3.29	3.37	3.45	3.45	3.54	3.82	1.66	1.73	1.77
Quick Ratio	2.68	2.82	2.90	3.06	3.07	3.19	3.37	1.48	1.56	1.61
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	9,637	10,742	6,884	3,818	3,848	154	107	404	963	983
Operating Cash Flow to CapEx	145.87%	121.63%	28.84%	276.68%	280.50%	356.32%	25.12%	319.60%	353.71%	289.78%
Free Cash Flow to Firm to Interest Expense	1,567.17	2,259.97	1,307.96	654.40	681.46	27.88	19.00	0.00	170.07	0.00
Operating Cash Flow to Interest Expense	10.25	13.79	2.50	17.34	18.70	23.49	1.58	0.00	19.47	0.00
Operating Cash Flow Less CapEx to Interest Expense	3.22	2.45	-6.17	11.07	12.04	16.90	-4.71	0.00	13.96	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.18	0.22	0.32	0.41	0.42	0.60	0.61	0.67	0.66	0.65
Accounts Receivable Turnover	12.24	12.68	12.13	12.03	12.66	12.16	12.18	12.04	12.39	11.91
Inventory Turnover	12.56	11.50	12.83	16.01	15.86	17.71	19.58	22.10	20.73	22.21
Fixed Asset Turnover	85.58	84.64	84.89	87.58	85.76	84.39	88.28	87.38	85.02	83.54
Accounts Payable Turnover	13.85	15.67	17.37	13.67	15.61	16.64	20.04	21.11	23.69	19.57
Days Sales Outstanding (DSO)	29.83	28.78	30.10	30.33	28.83	30.01	29.98	30.33	29.45	30.65
Days Inventory Outstanding (DIO)	29.07	31.75	28.45	22.79	23.01	20.62	18.64	16.51	17.61	16.43
Days Payable Outstanding (DPO)	26.36	23.29	21.02	26.69	23.38	21.93	18.21	17.29	15.41	18.65
Cash Conversion Cycle (CCC)	32.54	37.23	37.53	26.43	28.47	28.70	30.40	29.55	31.65	28.44
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	6,729	2,963	2,939	2,910	2,836	2,784	2,770	1,918	1,842	1,767
Invested Capital Turnover	0.20	0.25	0.39	0.52	0.54	0.91	0.92	1.08	1.11	1.13
Increase / (Decrease) in Invested Capital	-9,687	-13,413	-6,938	-3,869	-3,893	-179	-168	-992	-994	-1,017
Enterprise Value (EV)	4,774	4,485	4,859	4,759	3,608	4,026	2,981	2,074	1,906	1,841
Market Capitalization	4,098	3,830	4,212	4,144	3,066	3,568	2,500	1,659	1,572	1,565
Book Value per Share	$37.44	$14.25	$14.09	$14.02	$13.91	$14.05	$13.65	$8.86	$8.81	$8.66
Tangible Book Value per Share	($4.01)	($3.72)	($3.68)	($3.43)	($3.08)	($2.57)	($2.38)	($1.94)	($1.59)	($1.30)
Total Capital	7,628	3,881	3,827	3,869	3,866	3,908	3,868	3,080	3,086	3,065
Total Debt	1,576	1,573	1,536	1,574	1,572	1,582	1,580	1,578	1,578	1,574
Total Long-Term Debt	1,576	1,573	1,536	1,574	1,572	1,582	1,580	1,027	1,027	1,024
Net Debt	676	655	648	615	542	458	482	416	334	276
Capital Expenditures (CapEx)	43	54	46	37	38	37	36	28	31	30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-23	-2.56	17	-21	-46	-55	-0.51	4.27	-16	-25
Debt-free Net Working Capital (DFNWC)	876	916	905	938	984	1,068	1,097	1,167	1,228	1,273
Net Working Capital (NWC)	876	916	905	938	984	1,068	1,097	616	677	722
Net Nonoperating Expense (NNE)	23	1,139	15	15	12	4.33	21	249	2.20	15
Net Nonoperating Obligations (NNO)	676	655	648	615	542	458	482	416	334	276
Total Depreciation and Amortization (D&A)	65	76	73	78	97	101	101	99	92	92
Debt-free, Cash-free Net Working Capital to Revenue	-1.01%	-0.11%	0.68%	-0.83%	-1.79%	-2.12%	-0.02%	0.16%	-0.61%	-0.98%
Debt-free Net Working Capital to Revenue	37.71%	38.04%	36.64%	37.05%	38.16%	41.06%	41.90%	44.71%	47.42%	49.55%
Net Working Capital to Revenue	37.71%	38.04%	36.64%	37.05%	38.16%	41.06%	41.90%	23.60%	26.15%	28.11%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.45)	($23.35)	($0.42)	($0.40)	($0.35)	($0.17)	($0.49)	($4.92)	($0.19)	($0.27)
Adjusted Weighted Average Basic Shares Outstanding	161.73M	161.46M	162.92M	164.17M	165.12M	164.58M	167.73M	170.23M	171.50M	170.56M
Adjusted Diluted Earnings per Share	($0.45)	($23.35)	($0.42)	($0.40)	($0.35)	($0.17)	($0.49)	($4.92)	($0.19)	($0.27)
Adjusted Weighted Average Diluted Shares Outstanding	161.73M	161.46M	162.92M	164.17M	165.12M	164.58M	167.73M	170.23M	171.50M	170.56M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	161.93M	162.62M	163.67M	164.95M	165.56M	167.04M	169.59M	171.22M	172.17M	173.67M
Normalized Net Operating Profit after Tax (NOPAT)	-47	-23	-44	-41	-41	-21	-54	-34	-28	-30
Normalized NOPAT Margin	-7.61%	-3.55%	-7.01%	-6.33%	-6.20%	-3.17%	-8.35%	-5.36%	-4.41%	-4.61%
Pre Tax Income Margin	-12.21%	-597.75%	-10.89%	-10.14%	-9.02%	-3.84%	-12.26%	-129.78%	-5.07%	-7.52%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-11.92	-802.40	-13.72	-12.31	-11.78	-6.06	-15.49	0.00	-7.45	0.00
NOPAT to Interest Expense	-8.17	-561.94	-10.25	-8.59	-8.02	-4.43	-10.80	0.00	-5.49	0.00
EBIT Less CapEx to Interest Expense	-18.95	-813.74	-22.39	-18.58	-18.45	-12.65	-21.77	0.00	-12.95	0.00
NOPAT Less CapEx to Interest Expense	-15.19	-573.28	-18.92	-14.86	-14.69	-11.03	-17.08	0.00	-10.99	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Teladoc Health's Financials

When does Teladoc Health's financial year end?

According to the most recent income statement we have on file, Teladoc Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Teladoc Health's net income changed over the last 10 years?

Teladoc Health's net income appears to be on an upward trend, with a most recent value of -$1.00 billion in 2024, rising from -$17.04 million in 2014. The previous period was -$220.37 million in 2023. View Teladoc Health's forecast to see where analysts expect Teladoc Health to go next.

What is Teladoc Health's operating income?

Teladoc Health's total operating income in 2024 was -$1.02 billion, based on the following breakdown:

Total Gross Profit: $1.82 billion
Total Operating Expenses: $2.84 billion

How has Teladoc Health revenue changed over the last 10 years?

Over the last 10 years, Teladoc Health's total revenue changed from $43.53 million in 2014 to $2.57 billion in 2024, a change of 5,803.3%.

How much debt does Teladoc Health have?

Teladoc Health's total liabilities were at $2.03 billion at the end of 2024, a 2.0% decrease from 2023, and a 5,146.2% increase since 2014.

How much cash does Teladoc Health have?

In the past 10 years, Teladoc Health's cash and equivalents has ranged from $42.82 million in 2017 to $1.30 billion in 2024, and is currently $1.30 billion as of their latest financial filing in 2024.

How has Teladoc Health's book value per share changed over the last 10 years?

Over the last 10 years, Teladoc Health's book value per share changed from -34.41 in 2014 to 8.66 in 2024, a change of -125.2%.

Related Companies

This page (NYSE:TDOC) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Teladoc Health (TDOC) Financials

Frequently Asked Questions About Teladoc Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Teladoc Health (TDOC) Financials

Annual Income Statements for Teladoc Health

Quarterly Income Statements for Teladoc Health

Annual Cash Flow Statements for Teladoc Health

Quarterly Cash Flow Statements for Teladoc Health

Annual Balance Sheets for Teladoc Health

Quarterly Balance Sheets for Teladoc Health

Annual Metrics and Ratios for Teladoc Health

Quarterly Metrics and Ratios for Teladoc Health

Frequently Asked Questions About Teladoc Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools